Efficacy Of OjemdaThe durability of response continues even after discontinuation of Ojemda, making it a reliable treatment option.
Financial PositionDay One Biopharmaceuticals reported a robust cash position of $473 million, a best-in-class commercial product, an experienced management team, and is currently at its lowest valuation in over 30 months, presenting a buying opportunity with a holding period of at least 12 months.
Market PotentialReaffirming commercial trajectory: real-world momentum mirrors clinical confidence, with over 1,600 prescriptions written and $57.2M in net sales achieved, validating market readiness and unmet need.